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As flattening filter-free (FFF) photon beams become readily available for treat-
ment delivery in techniques such as SBRT, thorough investigation of skin dose 
from FFF photon beams is necessary under clinically relevant conditions. Using a 
parallel-plate PTW Markus chamber placed in a custom water-equivalent phantom, 
surface-dose measurements were taken at 2  × 2, 3 × 3, 4 × 4, 6 × 6, 8 × 8, 10 × 
10, 20 × 20, and 30 × 30 cm2 field sizes, at 80, 90, and 100 cm source-to-surface 
distances (SSDs), and with fields defined by jaws and multileaf collimator (MLC) 
using multiple beam energies (6X, 6XFFF, 10X, and 10XFFF). The same set 
of measurements was repeated with the chamber at a reference depth of 10 cm. 
Each surface measurement was normalized by its corresponding reference depth 
measurement for analysis. The FFF surface doses at 100 cm SSD were higher 
than flattened surface doses by 45% at 2 × 2 cm2 to 13% at 20 × 20 cm2 for 
6 MV energy. These surface dose differences varied to a greater degree as energy 
increased, ranging from +63% at 2 × 2 cm2 to -2% at 20 × 20 cm2 for 10 MV. At 
small field sizes, higher energy increased FFF surface dose relative to flattened 
surface dose; while at larger field sizes, relative FFF surface dose was higher for 
lower energies. At both energies investigated, decreasing SSD caused a decrease 
in the ratios of FFF-to-flattened surface dose. Variability with SSD of FFF-to-
flattened surface dose differences increased with field size and ranged from 0% 
to 6%. The field size at which FFF and flattened beams gave the same skin dose 
increased with decreasing beam energy. Surface dose was higher with MLC fields 
compared to jaw fields under most conditions, with the difference reaching its 
maximum at a field size between 4 × 4 cm2 and 6 × 6 cm2 for a given energy and 
SSD. This study conveyed the magnitude of surface dose in a clinically meaning-
ful manner by reporting results normalized to 10 cm depth dose instead of depth  
of dose maximum.
PACS number(s): 87.53.Bn, 87.53.Ly, 87.55.-x, 87.55.N-, 87.56.N-
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I. INTRODUCTION
The removal of the flattening filter in conventional medical linear accelerators produces a beam 
with decreased average energy, since lower-energy photons are no longer attenuated. In turn, the 
unattenuated beam increases monitor unit efficiency. The primary contributor of head scatter 
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reaching the patient or phantom in flattened beams is mainly due to the flattening filter; therefore, 
removal of the filter greatly decreases head scatter which can lead to decreased out-of-field dose.(1) 
Perhaps the greatest benefit of beams without the flattening filter in place, herein referred to 
as FFF beams, is the large increase in dose rate, up to four times that of flattened beams. The 
high dose rates achievable with unflattened beams greatly reduce treatment times, minimizing 
intrafraction motion and, in some cases, enabling beneficial techniques such as breath-hold or 
active breathing control to be used for otherwise ineligible patients at our institution.
Early investigations into the dosimetric properties of FFF beams were performed on modi-
fied linacs with the flattening filter manually moved out of the beamline.(2,3) Linacs with FFF 
beams have since been released by vendors and implemented clinically at many institutions. 
Properties of the FFF beams for these machines, usually determined during the commissioning 
process, have been subsequently reported.(4–6) Comparisons between Monte Carlo calculations 
and experimental measurements have been performed to confirm that simulations accurately 
model accelerator geometry.(7–9)
While much has been reported on depth-dose properties of unflattened beams, limited data 
on surface dose of these beams were reported by the previously mentioned investigations. 
A study by Wang et al.(10) specifically focused on the impact of flattening filter removal on 
superficial dose by measuring ionization curves in the buildup region with various field sizes 
made using jaws and multileaf collimators (MLCs) together. However, only a single source-
to-surface distance (SSD) was used, and reported measurements were normalized by the same 
maximum depth dose of a 10 × 10 cm2 field size. The goal of this investigation is to measure 
skin dose of FFF beams under clinically relevant conditions. In this study, we report skin dose 
measurements over a large range of field sizes at multiple SSDs using both fields made with 
collimator jaws and those made using the MLC alone.
 
II. MATERIALS AND METHODS
A.  Photon beams
Measurements were made using a Varian TrueBeam linear accelerator (Varian Medical Systems, 
Palo Alto, CA) which was commissioned in June 2013 for flattened photon beams and has since 
been used for clinical treatments. In October 2014, unflattened beams of energies 6 MV and 
10 MV were commissioned. The maximum dose rates were 600, 600, 1400, and 2400 MU/
min for the 6 MV flattened, 10 MV flattened, 6 MV FFF, and 10 MV FFF beams, respectively. 
For all measurements, 500 MU were delivered to minimize statistical uncertainty, and both the 
gantry and collimator angles were set at 0°.
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B.  Equipment
Skin dose was measured using a Markus parallel-plate ionization chamber (PTW Type 23343, 
PTW, Freiburg, Germany) which has a nominal sensitive volume of 0.055 cm3 (2.65 mm radius, 
2 mm depth) and an entrance foil thickness of 0.03 mm (polyethylene, 2.76 mg/cm2 density). 
The chamber was embedded in a custom-machined 25 × 25 × 5 cm3 Rexolite 1422 (cross-
linked polystyrene, density 1.05 g/cm3) phantom which was placed on top of solid water slabs 
of 10 cm thickness for backscatter, as shown in Fig. 1. Reference depth dose was obtained by 
placing an additional 10 cm thick solid water slab on the setup of Fig. 1. Measurements were 
made with a Keithley 35614 electrometer.
C.  Measurements
For each field size, SSD, and energy, four measurements were taken: two at +300 V bias and 
two at -300 V bias. These four measurements were averaged together to account for polarity 
bias of the chamber. As measurements were taken over several days, output measurements were 
made at the beginning of each session using the 10 × 10 cm2 jaw field size at 100 cm SSD and 
taken for each energy to correct for the daily variations in beam output.
To investigate the effect of field size on surface dose, field sizes of 2 × 2, 3 × 3, 4 × 4, 6 × 6, 
8 × 8, 10 × 10, 20 × 20, and 30 × 30 cm2 were first made using only the collimator jaws. The 
jaws were then set to 10 × 10 cm2, and the MLC was used to create the square fields of 2 × 2, 
3 × 3, 4 × 4, 6 × 6, and 8 × 8 cm2. This method of using MLCs to create fields more closely 
mimics the clinical scenario during stereotactic body radiotherapy (SBRT) treatments based 
on IMRT, where the jaws can be set to the maximum field size of all segments while the MLC 
leaves produce the smaller, complex shapes. A complete set of measurements were made at 
three SSDs: 80, 90, and 100 cm. All surface measurements were repeated for normalization 
purposes with the chamber at a depth of 10 cm (d10), achieved by adding 10 cm thick solid 
water on top of the detector. Diagrams of measurement geometries for surface and reference 
depth are shown in Fig. 2.
Fig. 1. Experimental measurement setup: (a) experimental setup is shown for surface measurements using the water-equiv-
alent phantom; (b) close-up view of the Markus chamber set in the custom-machined phantom for surface measurements.
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D.  Dose ratios
Absolute surface dosimetry is difficult; therefore, relative surface dose measurements were 
made by normalizing surface values to those at d10 for each field size (i.e., Dsurf / Dd10) and will 
herein be referred to simply as surface dose. A depth of d10 was chosen rather than depth of dose 
maximum (dmax) since 10 cm depth is closer to the clinically meaningful prescription point.
Markus chambers are widely used for surface measurements, but they require correction 
factors, which are functions of beam quality, to account for overresponse. Correction factors 
have previously been obtained through extrapolation chamber measurements,(11) but were 
unavailable at our institution. Instead, the effect of chamber response was minimized by taking 
the ratio of surface doses (e.g., (Dsurf/Dd10)
FFF / (Dsurf/Dd10)
flattened), enabling investigation into 
the effects of collimation type, field size, SSD, and the flattening filter.
 
III. RESULTS 
As measurements were performed over several weeks, separate surface measurements were 
performed during each session to account for daily variability in beam output and were obtained 
for all energies using a 10 × 10 cm2 jaw field. The output-corrected values were used in the 
analyses of the following subsections.
Fig. 2. Diagrams of measurement geometries are shown for (a) surface measurements and (b) reference (10 cm) depth 
measurements. The appropriate SSD was maintained when switching between the two geometries.
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A.  Flattened versus FFF
Measurements were taken under all setup conditions for both flattened and FFF beams. The 
ratios of FFF to flattened surface dose are shown in Fig. 3. A decrease in the ratio was observed 
with both increasing field size and decreasing SSD. 6 MV surface dose ratios showed less 
variation than 10 MV ratios across the range of field sizes investigated. For small jaw field 
sizes, SSD had little effect on the ratio; however, as field size was increased, the ratios at the 
differing SSDs showed greater difference. For example, at 2 × 2 cm2 jaw field size, surface 
dose ratios differed from 80 cm SSD to 100 cm SSD by 0.8% and 0.0% for 6 MV and 10 MV, 
respectively. However, at 20 × 20 cm2 field size, these differences in ratios increased to 4.5% 
and 6.9%. Similar trends were observed for MLC fields.
At the smallest field sizes (≤ 3 × 3 cm2), surface dose of FFF beams was about 63% greater 
than flattened beams at 10 MV and approximately 45% greater at 6 MV using jaw fields. The 
increase in surface dose at small field sizes for FFF beams was slightly reduced when using 
MLC fields to about 55% and 43% for 10 MV and 6 MV, respectively.
Fig. 3. Ratios of FFF-to-flattened surface dose are shown as a function of field size in water-equivalent phantom for jaw 
fields (left) and MLC fields (right). For MLC fields, jaws were set to 10 × 10 cm2. Each surface measurement was first 
normalized by the reference d10 measurement of the same field size. The same legend applies to both subfigures.
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B.  MLC versus jaw fields
The ratios of surface dose with MLC fields to surface dose with jaw fields are shown in Fig. 4. 
A peak in observed difference in dose between MLC and jaw fields was seen at 4 × 4 cm2 field 
size for 10 MV beams. At all SSDs, the ratio between MLC and jaw field measurements was 
relatively stable across field sizes for FFF beams (average arithmetic range in ratios across 
field size of 0.019, taken across all SSDs and energies); whereas larger variability was seen for 
flattened beams (average arithmetic range in ratios across field size of 0.045).
Fig. 4. Ratios of MLC-to-jaw field surface dose in water-equivalent phantom at each energy as a function of field size 
at 100 cm SSD. For MLC fields, jaws were set to 10 × 10 cm2. Each surface measurement was first normalized by the 
reference d10 measurement of the same field size.
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C.  Reference depth-dose comparison
The differences in dose at d10 between FFF and flattened beams are shown in Fig. 5. Because 
no beam tuning to match FFF beams with their corresponding flattened beams was made for 
the TrueBeam, the dose difference at d10 is expected even for the 10 × 10 cm
2 reference field. 
With increasing field size, flattened dose became increasingly larger (by about 8% at 30 × 
30 cm2). As field size increased, the scatter contribution to reference depth dose increased 
as well. However due to the flatness of the dose profile across the field, flattened dose varied 
strongly with field size, explaining the observed difference in d10 dose. This effect was present 
in the surface dose results of Figs. 3 and 4.
D.  Uncertainty analysis
Uncertainty of the reported ratios was calculated via measurement error propagation. The 
electrometer reported collected charge with 1 pC precision. Based on the variance of repeat 
measurements for each data point, the standard deviation of the FFF-to-flattened ratios for 
6 MV beam energy at 100 cm SSD was 0.0008 on average across field sizes from 2 × 2 cm2 to 
20 × 20 cm2 and ranged from 0.0003 to 0.0016. This uncertainty was relatively small compared 
to the magnitude of the ratios (< 0.2%). The variability at other energies and SSDs and for 
MLC-to-jaw ratios was of similar magnitude.
 
IV. DISCUSSION
Removal of the flattening filter affects surface dose in numerous ways. The decrease in treatment 
head scatter of the photon portion of the incident beam, as described in the Introduction, leads 
to a reduction in dose at all depths. More important for surface dose is the change in electron 
composition of the beam, which is the primary contributor of skin dose. A number of photons 
generated in the target interact with the target itself to produce secondary electrons which can 
travel downstream.(12) Accelerators built with flattening filter-free capabilities, such as the 
Varian TrueBeam, have filters above the monitor chambers to remove electron contamination. 
However, contaminant electrons are still allowed to reach the patient.
Fig. 5. FFF-to-flattened depth-dose differences. Percentage differences between FFF and flattened doses at a reference 
depth of 10 cm.
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With external beam radiotherapy, surface dose is essentially a function of prescription dose. 
By prescribing to shallower depths, the surface dose decreases. Studies often report surface 
dose as a percentage of that at dmax which is much greater and therefore may bias one into 
 thinking surface dose is relatively low. Yet tumors and their prescription points are often located 
at depths well beyond dmax. Thus, it is more clinically useful to use d10 as the reference depth 
for surface dose reporting, as has been done in this study.
Field size determines the surface dose of a given beam, as well. Flattened and unflattened 
beams are affected differently by both field size and the attenuation devices used to create the 
fields. With the flattening filter in place, differential attenuation of both photons and contaminant 
electrons occurs across the width of the field, with less attenuation occurring peripherally. It 
is expected, and observed in Fig. 4, that flattening filter-free beams show little variation with 
field size since equal filtration occurs across the entire field width.
When MLC leaves are in the path of the beam, photons of the primary beam interact with 
the MLC material and generate scattered photons and secondary electrons. Electrons of this 
nature which reach the surface mostly originate along the inner vertical edges of the collimator 
and have angular distributions which increase with energy. The additional electrons cause an 
elevation in surface dose. A peak in surface dose ratio of MLC-to-jaw fields is evident for the 
10 MV FFF beam in Fig. 4 at a field size of about 4 × 4 cm2. We suspect that this peak is due 
to the trade-off between the number of electrons being produced in the MLC leaves and the 
distance of the MLC leaves to the point of measurement. However, this supposition requires 
future Monte Carlo simulation for validation.
Clinical use of unflattened photon beams in radiotherapy holds most promise with hypo-
fractionated SBRT treatments where large doses are delivered in a small number of fractions. 
If flattened and FFF beams are calibrated identically (e.g., to deliver 1 cGy at reference depth 
per monitor unit), then the use of FFF beams will increase efficiency by shortening treatment 
time. On a TrueBeam, an unflattened beam can be delivered at a dose rate four times larger than 
the flattened counterpart at 10 MV (more than twice as large at 6 MV), which would enable 
beam-on time reductions of one half to one quarter. This increase in treatment efficiency only 
applies to beam-on time, so longer treatments such as SBRT cases would see the maximum 
benefit in using unflattened beams. SBRT commonly utilizes either arcs or multiple beams to 
increase dose falloff. However, this does not necessarily guarantee that there will be no skin 
complication. In fact, skin complication can be severe in SBRT because of its hypofraction-
ated nature resulting in high-fractional dose. Serious skin complications have been reported 
with SBRT.(13) In addition, from time to time, the desire of having a greater number of beams 
is compromised by the necessity of beam path avoidance for critical structures, resulting in 
increased skin dose in SBRT.
In principle, it may be possible to extract skin doses from commissioning data. However, 
depending on the situation, it may be difficult to accomplish in reality. The most common 
method of skin dose measurement in actual practice is to use a parallel-plate chamber with 
the necessary corrections applied as described in this study, which is the next best option after 
expensive and exhausting extrapolation chamber measurement. However, to the best of our 
knowledge, many users utilize a cylindrical chamber for beam scanning during commission-
ing. And it is well-known that cylindrical chambers suffer from significant volume averaging 
effect in high-gradient regions (e.g., buildup regions) which is worst at the surface. Thus, skin 
dose estimation from cylindrical chamber data is not reliable, and we therefore believe it is 
clinically useful to have skin dose data publicly available.  
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V. CONCLUSIONS
This study has investigated the ratios between skin doses with and without a flattening filter 
under conditions which are pertinent to modern treatment techniques involving beam modula-
tion. Surface measurements were evaluated as a function of both jaw-defined and MLC-defined 
field sizes and for multiple SSDs. From these data, the following conclusions can be drawn:
1.  As SSD increases, skin dose decreases relative to dose at depth.
2.  The difference in skin dose between MLC and jaw fields is less variable with field size for 
FFF beams compared to flattened beams.
3.  With increasing beam energy, field size has a greater effect on the difference in skin dose 
between FFF and flattened beams.
4.  Skin dose is higher with FFF beams at small field sizes than with flattened beams, while 
flattened beams give higher skin dose at large field sizes.
5.  The field size at which FFF and flattened beams give the same skin dose increases with 
decreasing beam energy.
To the best of the authors’ knowledge, this is the first study to evaluate surface dose as a 
function of (10 cm) depth dose which is more closely related to the treatment prescription point 
than dmax, enhancing clinical relevance.
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